Functionalization of cobalt porphyrin-phospholipid bilayers with his-tagged ligands and antigens

Nature Chemistry

Volumn 7, Issue 5, 2015, Pages 438-446

  Shao, Shuai ^a   Geng, Jumin ^b   Ah Yi, Hyun ^c   Gogia, Shobhit ^b   Neelamegham, Sriram ^b   Jacobs, Amy ^c   Lovell, Jonathan F ^a,b  

^a University at Buffalo The State University of New York   (United States)

^b the State University of New York   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COBALT; LIPID BILAYER; LIPOSOME; PHOSPHOLIPID; PORPHYRIN;

CHEMISTRY; LIPID BILAYER;

COBALT; LIPID BILAYERS; LIPOSOMES; PHOSPHOLIPIDS; PORPHYRINS;

EID: 84928542094     PISSN: 17554330     EISSN: 17554349     Source Type: Journal    
DOI: 10.1038/nchem.2236     Document Type: Article

References (49)

1. Brannon-Peppas, L. &Blanchette, J. O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 206-212 (2012
2. Purcell, A. W., McCluskey, J. &Rossjohn, J. More than one reason to rethink the use of peptides in vaccine design. Nature Rev. Drug Discov. 6, 404-414 (2007
3. Canalle, L. A., Lowik, D. W. P. M. &van Hest, J. C. M. Polypeptide-polymer bioconjugates. Chem. Soc. Rev. 39, 329-353 (2010
4. Nobs, L., Buchegger, F., Gurny, R. &Allemann, E. Current methods for attaching targeting ligands to liposomes and nanoparticles. J. Pharm. Sci. 93, 1980-1992 (2004
5. Algar, W. R. et al. The controlled display of biomolecules on nanoparticles: a challenge suited to bioorthogonal chemistry. Bioconjug. Chem. 22, 825-858 (2011
6. Sapra, P. &Allen, T. M. Ligand-targeted liposomal anticancer drugs. Prog. Lipid Res. 42, 439-462 (2003
7. Kirpotin, D. et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 36, 66-75 (1997
8. Yang, T. et al. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J. Control. Release 120, 169-177 (2007
9. Mastrobattista, E., Koning, G. A. &Storm, G. Immunoliposomes for the targeted delivery of antitumor drugs. Adv. Drug Deliv. Rev. 40, 103-127 (1999
10. Said Hassane, F., Frisch, B. &Schuber, F. Targeted liposomes: convenient coupling of ligands to preformed vesicles using 'click chemistry'. Bioconjug. Chem. 17, 849-854 (2006
11. Watson, D. S. &Szoka, F. C. Jr. Role of lipid structure in the humoral immune response in mice to covalent lipid-peptides from the membrane proximal region of HIV-1 gp41. Vaccine 27, 4672-4683 (2009
12. Liang, M. T., Davies, N. M. &Toth, I. Encapsulation of lipopeptides within liposomes: effect of number of lipid chains, chain length and method of liposome preparation. Int. J. Pharm. 301, 247-254 (2005
13. Pihlgren, M. et al. TLR4-and TRIF-dependent stimulation of B lymphocytes by peptide liposomes enables T cell-independent isotype switch in mice. Blood 121, 85-94 (2013
14. Blanco-Canosa, J. B. et al. Recent progress in the bioconjugation of quantum dots. Coord. Chem. Rev. 263-264, 101-137 (2014
15. Terpe, K. Overview of tag protein fusions: from molecular and biochemical fundamentals to commercial systems. Appl. Microbiol. Biotechnol. 60, 523-533 (2003
16. Arnau, J., Lauritzen, C., Petersen, G. E. &Pedersen, J. Current strategies for the use of affinity tags and tag removal for the purification of recombinant proteins. Protein Expres. Purif. 48, 1-13 (2006
17. Kubalek, E.W., Le Grice, S. F. J. &Brown, P. O. Two-dimensional crystallization of histidine-tagged, HIV-1 reverse transcriptase promoted by a novel nickelchelating lipid. J. Struct. Biol. 113, 117-123 (1994
18. Dorn, I. T., Neumaier, K. R. &Tampe, R. Molecular recognition of histidine-tagged molecules by metal-chelating lipids monitored by fluorescence energy transfer and correlation spectroscopy. J. Am. Chem. Soc. 120, 2753-2763 (1998
19. Hussein, W. M., Ross, B. P., Landsberg, M. J., Hankamer, B. &McGeary, R. P. Synthetic approaches to functionalized lipids for protein monolayer crystallizations. Curr. Org. Chem. 13, 1378-1405 (2009
20. Platt, V. et al. Influence of multivalent nitrilotriacetic acid lipid?ligand affinity on the circulation half-life in mice of a liposome-attached his6-protein. Bioconjug. Chem. 21, 892-902 (2010
21. Ruger, R., Muller, D., Fahr, A. &Kontermann, R. E. In vitro characterization of binding and stability of single-chain Fv Ni-NTA-liposomes. J. Drug Target. 14, 576-582 (2006
22. Xie, J., Lee, S. &Chen, X. Nanoparticle-based theranostic agents. Adv. Drug Deliv. Rev. 62, 1064-1079 (2010
23. Lovell, J. F. et al. Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents. Nature Mater. 10, 324-332 (2011
24. Lovell, J. F. et al. Enzymatic regioselection for the synthesis and biodegradation of porphysome nanovesicles. Angew. Chem. Int. Ed. 51, 2429-2433 (2012
25. Carter, K. A. et al. Porphyrin-phospholipid liposomes permeabilized by near-infrared light. Nature Commun. 5, 3546 (2014
26. Rieffel, J. et al. Hexamodal imaging with porphyrin-phospholipid-coated upconversion nanoparticles. Adv. Mater. 27, 1785-1790 (2015
27. Pasternack, R. F., Francesconi, L., Raff, D. &Spiro, E. Aggregation of nickel(II), copper(II), and zinc(II) derivatives of water-soluble porphyrins. Inorg. Chem. 12, 2606-2611 (1973
28. Constable, E. C. &Housecroft, C. E. Coordination chemistry: the scientific legacy of Alfred Werner. Chem. Soc. Rev. 42, 1429-1439 (2013
29. Wegner, S. V. &Spatz, J. P. Cobalt(III) as a stable and inert mediator ion between NTA and his6-tagged proteins. Angew. Chem. Int. Ed. 52, 7593-7596 (2013
30. Terekhov, S. N., Galievsky, V. A., Chirvony, V. S. &Turpin, P-Y. Resonance Raman and absorption characterization of cationic Co(II)-porphyrin in its complexes with nucleic acids: binding modes, nucleic base specificity and role of water in Co(II) oxidation processes. J. Raman Spectrosc. 36, 962-973 (2005
31. Ruoslahti, E. Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv. Mater. 24, 3747-3756 (2012
32. Pasqualini, R., Koivunen, E. &Ruoslahti, E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nature Biotechnol. 15, 542-546 (1997
33. Danhier, F., Breton, A. L. &Preat, V. RGD-based strategies to target alpha (v) beta(3) integrin in cancer therapy and diagnosis. Mol. Pharm. 9, 2961-2973 (2012
34. Bloch, S. et al. Targeting beta-3 integrin using a linear hexapeptide labeled with a near-infrared fluorescent molecular probe. Mol. Pharm. 3, 539-549 (2006
35. Cai, W. et al. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett. 6, 669-676 (2006
36. Hong, G. et al. Near-infrared-fluorescence-enhanced molecular imaging of live cells on gold substrates. Angew. Chem. Int. Ed. 50, 4644-4648 (2011
37. Janib, S. M., Moses, A. S. &MacKay, J. A. Imaging and drug delivery using theranostic nanoparticles. Adv. Drug Deliv. Rev. 62, 1052-1063 (2010
38. Sperling, R. A., Gil, P. R., Zhang, F., Zanella, M. &Parak, W. J. Biological applications of gold nanoparticles. Chem. Soc. Rev. 37, 1896-1908 (2008
39. Tam, N. C. M., Scott, B. M. T., Voicu, D., Wilson, B. C. &Zheng, G. Facile synthesis of Raman active phospholipid gold nanoparticles. Bioconjug. Chem. 21, 2178-2182 (2010
40. Zwick, M. B. et al. Broadly neutralizing antibodies targeted to the membraneproximal external region of human immunodeficiency virus Type 1 glycoprotein gp41. J. Virol. 75, 10892-10905 (2001
41. Zwick, M. B. The membrane-proximal external region of HIV-1 gp41: a vaccine target worth exploring. AIDS 19, 1725-1737 (2005
42. Montero, M., van Houten, N. E., Wang, X. &Scott, J. K. The membraneproximal external region of the human immunodeficiency virus Type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol. Mol. Biol. Rev. 72, 54-84 (2008
43. Burton, D. R. et al. HIV vaccine design and the neutralizing antibody problem. Nature Immunol. 5, 233-236 (2004
44. Alam, S. M. et al. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl Acad. Sci. 106, 20234-20239 (2009
45. Matyas, G. R. et al. Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes. AIDS 23, 2069-2077 (2009
46. Verkoczy, L. et al. Induction of HIV-1 broad neutralizing antibodies in 2f5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses. J. Immunol. 191, 2538-2550 (2013
47. Watson, D. S., Platt, V. M., Cao, L., Venditto, V. J. &Szoka, F. C. Antibody response to polyhistidine-tagged peptide and protein antigens attached to liposomes via lipid-linked nitrilotriacetice acid in mice. Clin. Vaccine Immunol. 18, 289-297 (2011
48. Dayananda, K. M., Gogia, S. &Neelamegham, S. Escherichia coli-derived von Willebrand factor-A2 domain fluorescence/Forster resonance energy transfer proteins that quantify ADAMTS13 activity. Anal. Biochem. 410, 206-213 (2011
49. Yi, H. A., Diaz-Aguilar, B., Bridon, D., Quraishi, O. &Jacobs, A. Permanent inhibition of viral entry by covalent entrapment of HIV gp41 on the virus surface. Biochemistry 50, 6966-6972 (2011